Chugai Pharmaceutical Co Ltd (4519) - Financial and Strategic SWOT Analysis Review

Chugai Pharmaceutical Co Ltd (4519) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Chugai Pharmaceutical Co Ltd (Chugai), a subsidiary of Hoffmann-La Roche Ltd, focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone and joint diseases; renal diseases; immunology and infectious diseases and others. It also offers drugs to aid kidney, liver and other organ transplantations. It also has a range of product candidates in its pipeline. Operating through its network of subsidiaries, the company offers its pharmaceutical products in overseas markets including North America, Europe and Asia. Chugai is headquartered in Tokyo, Japan.

Chugai Pharmaceutical Co Ltd Key Recent Developments

Mar 05,2020: Roche wins Chinese approval for Actemra to combat coronavirus complications
Feb 07,2020: Chugai supports National Cancer Center Japan for an Investigator-Initiated Clinical Study based on patient-requested therapy system
Jan 30,2020: Chugai announces 2019 full year results and forecasts for 2020
Sep 30,2019: A Treatment Support Tool Using a Private Medical Care SNS Becomes Available in Rheumatoid Arthritis, Lupus Nephritis, and Chronic Kidney Disease
Jul 30,2019: Chugai Continues to be Listed for All ESG Indices Selected by GPIF

Key benefits of buying this profile include:


You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company
 


Section 1 - About the Company
Chugai Pharmaceutical Co Ltd - Key Facts
Chugai Pharmaceutical Co Ltd - Key Employees
Chugai Pharmaceutical Co Ltd - Key Employee Biographies
Chugai Pharmaceutical Co Ltd - Major Products and Services
Chugai Pharmaceutical Co Ltd - History
Chugai Pharmaceutical Co Ltd - Company Statement
Chugai Pharmaceutical Co Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Chugai Pharmaceutical Co Ltd - Business Description
Business Segment: Pharmaceutical Sales
Performance
Business Segment: Pharmaceuticals
Overview
Business Segment: Royalties and Other Operating Income
Performance
Geographical Segment: Japan
Performance
Geographical Segment: Overseas
Performance
R&D Overview
Chugai Pharmaceutical Co Ltd - Corporate Strategy
Chugai Pharmaceutical Co Ltd - SWOT Analysis
SWOT Analysis - Overview
Chugai Pharmaceutical Co Ltd - Strengths
Chugai Pharmaceutical Co Ltd - Weaknesses
Chugai Pharmaceutical Co Ltd - Opportunities
Chugai Pharmaceutical Co Ltd - Threats
Chugai Pharmaceutical Co Ltd - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Chugai Pharmaceutical Co Ltd, Recent Deals Summary
Section 5 – Company’s Recent Developments
Mar 05, 2020: Roche wins Chinese approval for Actemra to combat coronavirus complications
Feb 07, 2020: Chugai supports National Cancer Center Japan for an Investigator-Initiated Clinical Study based on patient-requested therapy system
Jan 30, 2020: Chugai announces 2019 full year results and forecasts for 2020
Sep 30, 2019: A Treatment Support Tool Using a Private Medical Care SNS Becomes Available in Rheumatoid Arthritis, Lupus Nephritis, and Chronic Kidney Disease
Jul 30, 2019: Chugai Continues to be Listed for All ESG Indices Selected by GPIF
Jul 25, 2019: Chugai announces 2019 Half Year Results
Jun 14, 2019: Chugai and Mitsubishi Logistics Enter into Service Agreement for Logistics Operations
May 23, 2019: Chugai Pharmaceutical to build new $1bn research lab in Japan
May 21, 2019: Establishment of Chugai Life Science Park Yokohama and Relocation of Research Laboratories
Apr 24, 2019: Construction of a new manufacturing building for active pharmaceutical ingredients to further accelerate development of small and middle molecule drugs
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
 


List Of Tables


Chugai Pharmaceutical Co Ltd, Key Facts
Chugai Pharmaceutical Co Ltd, Key Employees
Chugai Pharmaceutical Co Ltd, Key Employee Biographies
Chugai Pharmaceutical Co Ltd, Major Products and Services
Chugai Pharmaceutical Co Ltd, History
Chugai Pharmaceutical Co Ltd, Other Locations
Chugai Pharmaceutical Co Ltd, Subsidiaries
Chugai Pharmaceutical Co Ltd, Key Competitors
Chugai Pharmaceutical Co Ltd, Ratios based on current share price
Chugai Pharmaceutical Co Ltd, Annual Ratios
Chugai Pharmaceutical Co Ltd, Annual Ratios (Cont...1)
Chugai Pharmaceutical Co Ltd, Annual Ratios (Cont...2)
Chugai Pharmaceutical Co Ltd, Interim Ratios
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
Chugai Pharmaceutical Co Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
 


List Of Figures


Chugai Pharmaceutical Co Ltd, Performance Chart (2015 - 2019)
Chugai Pharmaceutical Co Ltd, Ratio Charts
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
Chugai Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020
 


Leading Pharmaceutical Contract Development Manufacturing Organizations

- Will the industry consolidate, decentralize, or undergo a bimodal transformation - How will the current trends affect the major market segments- Which companies will enter the market and which

USD 3500 View Report

Global Pharmaceutical Continuous Manufacturing Market 2023-2029

For decades, pharmaceutical firms have manufactured their products in batches. To streamline production, manufacturers have begun to apply continuous manufacturing technologies to the pharmaceutical production process. Continuous manufacturing is a

USD 2950 View Report

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available